BioMarin PharmaceuticalBMRN

NASDAQ · USA · Segment 3 of 8 in the Medicine, pharma & life science value chain: Biotech & innovation

Biopharma specialized in enzyme and gene therapies for rare genetic diseases.

Biotech & innovation: Innovation-driven biotech companies focused on novel treatment modalities.

Key metrics

Market cap

$11.6B

Price

$59.29

Today

−1.1%

Return YTD

+0.9%

Return 1Y

+0.5%

P/E

43.0

P/S

3.6

P/B

1.9

Data as of 2026-07-10 · updates daily after U.S. close

Theme exposure

Rare diseaseRare diseasesEnzyme therapyGene therapy

In the value chain

Products & services

Enzyme replacement therapies
Voxzogo (dwarfism)
Gene therapy (hemophilia)

Competitors

Sarepta Therapeutics
Ultragenyx
Vertex Pharmaceuticals

Risks

Rare-disease market
Gene therapy pricing

Same segment: Biotech & innovation

AmgenAMGN Gilead SciencesGILD Vertex PharmaceuticalsVRTX RegeneronREGN Alnylam PharmaceuticalsALNY ModernaMRNA BiogenBIIB IncyteINCY

See where BioMarin Pharmaceutical sits in the full Medicine, pharma & life science map — every segment from upstream suppliers to end markets, with daily metrics.Open the Life science value chain →